Vijaya Diagnostic Centre Limited has informed the Exchange regarding Appointment of Mr. S. Ramachandra Reddy as Interim Chief Financial Officer of the company w.e.f. May 12, 2025.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts less than Nifty Smallcap 250 and 3.5 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vijaya Diagnostic Centre's board met on May 12, 2025 and approved audited standalone and consolidated financial results for Q4 and the year ended March 31, 2025, with the statutory auditors issuing an unmodified (clean) opinion. The board recommended a final dividend of ₹2 per equity share (200% on a face value of ₹1), subject to shareholder approval at the upcoming AGM. Mr. S. Ramachandra Reddy, currently General Manager – Finance with over 12 years of experience (previously at Dr. Reddy's Laboratories and Coromandel International), was appointed as Interim Chief Financial Officer and Key Managerial Personnel. Separately, Mr. Lanka Sai Srinivas was appointed as Chief Technology Officer, bringing 24 years of IT experience from UnitedHealth Group and Wipro. The board also granted 1,91,150 ESOPs at an exercise price of ₹815 per share to eligible employees under the VDCL ESOP Plan 2018, and re-appointed M/s. Santhosh & Associates as cost auditors for FY 2025-26.
The clean audit opinion and consistent dividend payout signal steady financial health, which is positive for shareholders. The interim CFO appointment suggests a leadership transition at the finance helm — investors should watch for a permanent CFO announcement. The ESOP grant at a discounted exercise price reflects ongoing efforts to retain talent, with modest dilution of about 0.19% of equity (1.91 lakh shares).